VERDE SCIENCE STRENGTHENS SCIENTIFIC TEAM
02 10월 2014 - 10:00PM
InvestorsHub NewsWire

Richmond, BC - October 02,
2014 - InvestorsHub NewsWire - Verde Science, Inc. (VRCI-OTCQB)
a Medical Marijuana Research and Development Company, is pleased to
announce the expansion of its Research and Development capabilities
with the addition of its newest alliance partners, Dr. Ratnesh Jain
and Dr. Prajatka Dandekar Jain, both of whom earned their Ph.D.’s
in Pharmacology from the Institute of Chemical Technology, a
Mumbai, India based University with a research focus along the
entire spectrum of Chemical Engineering. Dr. Ratnesh Jain has
investigated the development and design of novel drug delivery
mechanisms which we believe will have significant applications in
the nascent field of Medical Marijuana treatment. This could
also be applied to clinical trials aimed at determining proper
dosing and drug formulations for various specific medical
issues.
Dr. Prajakta Dandekar Jain is an
Assistant Professor of Pharmaceutical Technology at the Institute
of Chemical Technology. In addition to research into novel
drug delivery systems, she has also focused much of her research on
nanoparticles, which will have particular relevance in the study of
medical uses of THC and cannabinoids, and nanoparticles of
hemp. Harp Sangha, Verde’s Chairman and CEO commented, “The
addition of Drs. Jain to our current in-house R&D staff in
Canada is going to be an immediate boost to our research
program. It enables us to begin on research and clinical
trials in India, which at the moment are on hold pending licensing
in Canada. This gives Verde a huge advantage.”
Verde’s Research and Development
Program will focus on developing custom medicinal formulations from
cannabinoids and THC compounds for the treatment of specific issues
such as migraines, glaucoma, loss of appetite from cancer
therapies, and numerous other medical issues. Verde also
plans to alpha test innovate growing technologies in India as part
of the company’s initiatives. (A more extensive background
statement for the Drs. Jain is available on the Verde Science
website: www.VerdeScienceInc.com.)
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a public
company trading under the symbol OTCQB:
VRCI. The Company is focused on Medical Marijuana
Research and Development, and providing advisory services, quality
assurance, and aeroponic growing systems in the burgeoning Medical
Marijuana industry to established, licensed growers throughout
Canada. The company has no operations anywhere in the United
States, it only operates where the laws are clearly defined for
this industry.
Safe Harbor Statements?Certain information
contained in this news release constitutes "forward-looking
statements" as such term is used in applicable United States and
Canadian laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as
"expects" or "does not expect", "is expected", "anticipates" or
"does not anticipate", "plans", "estimates", "intends" or
"believes", or that certain actions, events or results "may",
"could", "would", "might" or "will be taken", "occur", or "be
achieved". Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company's ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company's
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
For further information please contact:
Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca
Louis Silver, Director of Investor Relations
1-610-710-1303
lsilver@verdescienceinc.com
Verde Science (CE) (USOTC:VRCI)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Verde Science (CE) (USOTC:VRCI)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025